Obesity Paradox With Immunotherapy in NSCLC Obesity Paradox With Immunotherapy in NSCLC

A new analysis shows that overweight and obese patients with NSCLC live longer than their normal weight counterparts following treatment with immunotherapy.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news